Use of a GLP-1R Agonist to Treat Opioid Use Disorder

NCT04199728 · Completed

Last updated 2026-05-28

This clinical trial is testing whether a GLP-1 receptor agonist can help reduce cravings for opioids in adults receiving medication-assisted treatment for opioid use disorder.

Status Completed The study has finished.

Phase Phase1, Phase2

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 27 people

Who can join Ages 18–75 · all sexes

Timeline Started 2021-10 · est. completion 2023-09

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT04199728 ↗

Description as written by the study sponsor.

This research is being done to find out if liraglutide (brand name is Saxenda®) can safely and effectively reduce craving for opioids in patients with opioid use disorder, a primary factor contributing to early relapse.

Treatments tested

Liraglutide Pen Injector also known as Saxenda Drug

Liraglutide will be provided using an injection pen provided by the manufacturer
Placebo Drug

Placebo injection pen

Main thing measured	Change in Self-reported Cue-elicited Drug Craving as Measured by Visual Analog Scale (VAS)
Sponsor	Milton S. Hershey Medical Center
Conditions studied	Opiate Substitution Treatment, Opioid-Related Disorders
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04199728 ↗